Corrections

Corrections Log

When we find an error, we fix it and record it here: what was wrong, what we changed and when. Typo and formatting fixes are not listed.

How we handle corrections

Every article cites its sources, and we check those references against their PubMed records. When a claim does not match its source, we correct the claim, change the source or remove the claim. Substantive corrections, meaning changes to a fact, a figure, a recommendation or a source, are listed below with the date of the fix. How we check sources is described in our methodology. If you spot an error, please tell us through our contact page.

Sitewide corrections

  • October 2, 2026Corrected the author information across the site: an unsupported claim that Derek Giordano had spent over a decade synthesizing longevity research, shown on 115 article and guide pages, the About page and the author page, was replaced with his actual background. The author page no longer says the site is funded by display advertising and reader support (it carries no advertising), and its outdated statistics and references to letter grades the Supplement Evidence Database no longer uses were corrected.
  • October 2, 2026Corrected nutrition and supplement advice across the site: general protein targets of 1.2 to 2.2 g/kg a day on 6 articles and 8 guides now match the RDA and the expert recommendation for older adults; vitamin D doses above the 4,000 IU upper limit, a 40 to 60 ng/mL blood target and an inflated deficiency figure were replaced with NIH guidance on 11 pages; supplemental magnesium doses above the 350 mg upper limit were capped on 13 pages; and the rapamycin article no longer claims the drug extended lifespan in every model organism tested.
  • October 2, 2026Fixed the page structure of 18 articles: 12 were missing their opening body tag and 6 had content after their closing tags. On 4 peptide articles a duplicated script stopped FAQ answers from opening; they now open.
  • September 30 to October 1, 2026Re-checked every printed reference against its PubMed record, corrected wrong details, fixed 26 references that pointed at the wrong paper and replaced a retracted study.
  • September 30, 2026Removed an invented timeline of research results, including trial results that do not exist, from 19 pages and replaced it with verified milestones.
  • September 30, 2026Removed 12 studies from the Research Radar that we could not verify, along with their mentions in three tools. The Research Radar page is no longer indexed.
  • September 30 to October 1, 2026Deleted 26 quotes attributed to named scientists that we could not source.
  • October 1, 2026Every article now cites its sources: we added references, each checked against its PubMed record, to every article that lacked them.
  • October 1, 2026Rebuilt the supplement interaction checker: removed 16 interactions without solid evidence and re-sourced the remaining 16, each linked to its research.
  • October 1, 2026Relabelled the biological age questionnaire as an unvalidated lifestyle estimate (it had claimed to be derived from the PhenoAge model) and added a PhenoAge calculator that follows the published model.
  • October 1, 2026Removed three charts whose numbers we could not source and redrew the sleep-and-mortality chart from its source.
  • October 1, 2026Checked all 148 glossary definitions against published research and rewrote 113 of them: removed a clinical trial that does not exist, "optimal" lab ranges that no study supports and outdated claims (for example, that kidney-function equations use race). Each definition now links to its source.
  • October 1, 2026Rebuilt the lab results interpreter and the biomarker guide. Both had graded results against "optimal" ranges that no guideline supports (for example, HbA1c below 5.3% or vitamin D of 40 to 60 ng/mL) and used made-up grading rules. They now use the categories in clinical guidelines and NIH references, cite every cut-off, and say when a marker has no agreed range.
  • October 1, 2026Rebuilt the blood panel builder and the test guide. They had listed unverified lab order codes (one was the wrong test), exact prices that decided which tests you saw, invented "optimal" ranges and testing schedules that contradicted guidelines. They now suggest tests by scope and risk, follow published screening recommendations (for example, colorectal screening from 45 and bone density screening for women from 65), and cite their sources.
  • October 1, 2026Regraded the supplement evidence database and the longevity stack builder. Fish oil, vitamin D, niacin and magnesium had been graded A despite large trials finding no prevention benefit (VITAL, ASCEND) or, for niacin added to statins, no benefit and more side effects (AIM-HIGH, HPS2-THRIVE). Every grade now names the outcome it applies to, every listed study links to its PubMed record, and citations that could not be found or matched the wrong paper were removed. The stack builder's score is now an average, so adding weakly supported items lowers it, and its invented popularity percentages were removed.
  • October 1, 2026Rebuilt the gene variant lookup. It listed MTHFR and SOD2 genotypes in letters that raw 23andMe and AncestryDNA files never show (and mislabelled SOD2), reversed which CETP genotype was linked with longevity, reversed which SIRT1 genotype is common, told people with MTHFR variants to avoid folic acid (a randomized trial shows folic acid works for them) and misreported several study results. Every genotype is now listed the way raw files print it, with 41 sources.
  • October 3, 2026Added a disclosure that IQ Healthspan uses AI tools to help research, draft and fact-check articles, with every claim checked against the study it cites. It appears in the author card on articles, on the author page and in a new How we use AI section of the methodology page.
  • October 3, 2026Made article titles consistent: on a few articles the main heading or social-sharing title still showed wording from before an earlier correction (for example, the HRT article heading). Titles now change everywhere at once, and an automated check keeps the page title, heading, structured data and social titles in step.
  • October 3, 2026Removed internal production notes that were visible to readers on two articles (word counts and batch labels), replaced leftover references to old internal article numbers on six pages with links by name, and updated an outdated article count on the About page. Automated checks now block both.
  • October 3, 2026Corrected reference counts: on 45 articles, a note stating how many references the article lists had not been updated when references were added during our review. Every count now matches its list, and an automated check keeps them in sync.
  • October 3, 2026Removed overstated language from 11 articles and guides. Phrases such as "the most powerful longevity intervention", "dramatically" and "drive biological aging most aggressively" were replaced with what the cited studies support; for example, the Your 50s guide no longer says early detection improves survival for nearly every cancer, only for the cancers where screening is recommended, and the psychedelic medicine article now notes that the FDA declined to approve MDMA-assisted therapy in 2024.
  • October 3, 2026Checked every article and guide for sentences that state figures or attribute findings to "studies" without a citation. Four sentences gained citation markers to sources already listed on the page (hip fracture mortality, glucose responses to meals, the TRAVERSE testosterone trial). Three unsupported specifics were removed: a claim that time-restricted eating on 5 to 6 days a week is enough, six protein-quality (DIAAS) scores with no source, and a precise bedroom temperature range.
  • October 3, 2026Removed more overstated wording: the heart disease, type 2 diabetes and protocol-by-age pages no longer promise that interventions can "dramatically change your trajectory", the 2025 state-of-the-science article no longer calls cellular reprogramming potentially "dramatically larger than any other longevity intervention" without noting it is untested in humans, and the sleep apnea article no longer calls STOP-BANG the "most clinically validated" screening tool.
  • October 3, 2026Updated the tools and course that still cited the retired 2018 US cholesterol guideline. The biomarker guide, lab results interpreter, blood panel builder and test guide now cite the 2026 dyslipidemia guideline; the biomarker guide shows the 2026 LDL goals (under 100 mg/dL at borderline or intermediate risk, under 70 mg/dL at high risk); the Longevity Fundamentals course notes that the 2026 guideline kept statin treatment at an LDL of 190 mg/dL or more without a separate risk calculation; and the lab testing guide now describes the ApoB 130 mg/dL cut-off as the 2018 guideline's.
  • October 4, 2026Rebuilt the Supplement Brand Quality Guide. It had described 21 products as NSF certified; 8 of them (two Carlson, two Pure Encapsulations, a Garden of Life probiotic, a Sports Research collagen, a Nordic Naturals vitamin D3 and Thorne's US CoQ10) had no listing in NSF's public directories. The table now lists only the 14 products we found in those directories on October 4, 2026, each linked to its live listing. We also removed quality scores we had assigned without a method, undated prices, certification claims we could not check (USP, ConsumerLab, certificates of analysis), an unsourced claim that up to 90% of supplements fail testing, and a note on folic acid that contradicted our corrected guidance.
  • October 4, 2026Rewrote The State of Longevity Science: 2026. The April edition cited no sources and included details of a semaglutide extension study we could not verify, unsourced market-size figures, undated trial statuses and predictions for 2027 that had already come true or been overtaken (semaglutide was approved for fatty liver disease in 2025). The new edition summarizes the year's major trials, approvals and guidelines, with 13 references.
  • October 4, 2026Rewrote the six answers in the home page FAQ, which had never been checked against the rest of the site. They described the biological age questionnaire as a validated model, said the Supplement Evidence Database grades more than 40 compounds from A to D (it rates 25, without letter grades), pointed to optimal lab ranges we had already removed, advised a coronary calcium scan for everyone over 40 (the 2026 guideline uses it selectively), and gave unsourced market and price figures.
  • October 4, 2026Removed undated price ranges for tests and devices from the age guides, the lab results interpreter and three articles, and replaced two article-library descriptions that made claims their articles do not support. The lab results interpreter no longer advises a coronary calcium scan for everyone at 40 to 45, in line with the 2026 dyslipidemia guideline, or calls consumer epigenetic tests the gold standard.
  • October 4, 2026Corrected the home page tool and topic cards, which still described tools as they were before we rebuilt them: the biological age questionnaire as covering validated domains, the trial tracker as 24 curated trials including TAME (which is not registered), the brand guide as rating 40+ products on cost and purity, and the bloodwork course as teaching optimal ranges. Topic article counts, which added up to more than the number of articles on the site, now match each category page.
  • October 4, 2026Corrected descriptions of our tools in the site menu and on tool, category and reading-path pages. The menu described the brand guide as rating 40+ brands; the biological age calculator was described as covering validated domains (it offers a PhenoAge estimate from blood tests and a separate unvalidated questionnaire); the interaction checker claimed to cover 40+ compounds with cited research (it documents 16 interactions); and several pages still advertised optimal lab ranges and lab codes we had removed. The lab results interpreter no longer presents three consumer epigenetic tests as validated.
  • October 4, 2026Rebuilt all ten printable PDFs, which had never been checked. The bloodwork checklist printed "optimal" lab ranges that no outcome trials support (for example HbA1c under 5.2% and vitamin D of 40 to 60 ng/mL) and an unsourced testing schedule; the supplement tracker and protocol sheet advised 2,000 to 5,000 IU of vitamin D and magnesium above the 350 mg upper limit; other sheets gave bedroom temperatures, step targets and fitness benchmarks without sources. Every sheet now lists its sources. We also rebuilt the biomarker ranges widget offered for other websites, which showed invented optimal ranges, and retired four other widgets that repeated claims we had corrected.
  • October 4, 2026Changed the titles of four articles that claimed more than their evidence shows: coronary calcium scoring as the single best test, muscle as the most important organ, and VO2 max as the single best predictor of lifespan and the most important longevity biomarker. The articles report strong associations, not that any one measure is best. Also corrected tool descriptions in the site menu and on 217 pages: the dashboard does not track biological age or sleep, the nutrition calculator does not set meal timing, and the interaction checker documents no hormone therapy interactions.
  • October 4, 2026Corrected search-result and sharing descriptions that contradicted their pages. The rapamycin safety article's description said the drug extended lifespan in every model organism tested; the Your 60s guide described itself as the guide for your 50s; the fatty liver, menopause tracking, nutrition calculator, glossary, red light, methylene blue and women's exercise descriptions promised content the pages do not contain or gave figures they do not support. Sharing descriptions now match the search descriptions on every page.
  • October 4, 2026Rewrote the result messages of the biological age questionnaire, which gave figures and claims without sources: an "optimal" fasting glucose range of 70 to 85 mg/dL, a 10 to 15 percent VO2 max gain in three months, cortisol falling within eight weeks of meditation, and smoking damage reversing within five years. Corrected the Start Here reading path, which said four habits explain 70 to 80 percent of controllable lifespan variation (unsourced), and updated 82 related-article links that still showed older titles.
  • October 4, 2026Corrected the brain section of the omega-3 article, which said large trials had not challenged the evidence (the VITAL trial found no cognitive benefit from supplements), named a study incorrectly and gave a brain-age figure the study does not report; a sentence about the STRENGTH trial also cited the wrong paper. Added the 2026 VITAL result showing no effect of omega-3 on fractures, and a 2026 trial in which nicotinamide riboside raised NAD+ without improving memory. The lab testing guide now uses the 2026 cholesterol guideline for lipoprotein(a) and labels the 2018 thresholds as such.
  • October 4, 2026Removed figures from a retracted 2013 study of herbal supplements that remained in the text of the supplement safety article after its citation was deleted, and corrected the description of an analysis of FDA warnings about supplements with hidden drugs, which had been attributed to the wrong journal, year and reference.
  • October 4, 2026Replaced a table in the NAD+ and sirtuins article that rated exercise and fasting as very strong ways to raise NAD+ with tissue effects confirmed within 12 to 16 hours, none of which its sources support, with a sourced section that adds a 2026 trial. Relabelled the food-group table in the nutrition blueprint by type of evidence instead of unsourced strength ratings. Corrected four key-takeaway boxes: two sleep articles recommended a bedroom temperature range with no source, the sauna article gave mortality figures that do not match the Finnish study, and the brain article cited the 2020 Lancet Commission without its 2024 update.
  • October 4, 2026Changed the titles of seven more articles that claimed more than their content supports, including cellular senescence as cells that are aging you, iron imbalance as accelerating aging, and thyroid function as something most adults never optimize (the article reports that treating mild thyroid changes in older adults showed no benefit). Updated search breadcrumbs that still showed older titles on eight pages.
  • October 4, 2026Expanded the sleep optimization guide, which had been cut to about 500 words while its title promised every evidence-based strategy, with sourced sections on sleep regularity, light exposure, alcohol and what sleep apnea treatment does and does not do, and changed its title to match. Changed the title of the epigenetic diet article, which promised foods that reprogram gene expression although the article explains that such claims rest mostly on laboratory studies, and added the two best-known human trials with their limits.
  • October 4, 2026Added human evidence to three short articles and changed their titles to match: the AMPK article now reports that hard exercise, but not 90 minutes of easy cycling, switches on the cellular energy sensor AMPK in human muscle, and that the drug metformin's link to AMPK is debated; the metabolic flexibility article adds a training trial; the purpose and mindset article adds three studies. The MOTS-c article no longer describes easy endurance training and time-restricted eating as proven ways to activate AMPK.
  • October 4, 2026Corrected claims that spreading protein evenly across meals matters especially for older adults: the supporting studies were in eight young-to-middle-aged adults and in trained young men, and an eight-week trial in older adults found no difference in lean mass, strength or function (protein, protein timing and time-restricted eating articles). Added plant versus animal protein evidence. Removed descriptions of epigenetic clocks as clinically relevant or able to measure biological age to the year, and added evidence that repeat measurements of the same sample can differ by up to nine years.
  • October 4, 2026Added evidence that makes three articles more complete: the autophagy article now reports that two randomized trials of urolithin A, a supplement promoted for cellular renewal, missed their main muscle outcomes (its section heading promising three pathways of autophagy was also corrected); the debunked anti-aging claims article notes the one debated positive brain-training result; and the supplement testing article describes what USP and NSF certification check and how to confirm a seal in the certifier's directory.
  • October 4, 2026Fixed two pages whose search-result titles showed raw formatting code, and added the first placebo-controlled trial of senolytic drugs in older adults to the cellular senescence article: in 60 postmenopausal women, dasatinib plus quercetin did not reduce bone breakdown, the trial's main measure.
  • October 5, 2026Merged our two overlapping pages on longevity by age into one, Longevity Protocol by Age, which now also covers the classic trial in which frail nursing-home residents in their 80s and 90s more than doubled their strength with resistance training; the old address redirects to it.

Page corrections

  • October 2026Grounding review: Removed a "2025 South Korean trial" that does not exist; it had been presented as the main evidence.
  • October 2026Budget longevity protocol: Removed a default of 5,000 IU of vitamin D a day for everyone, which is above the 4,000 IU upper limit; vitamin D advice now follows the Endocrine Society's 2024 guideline. Corrected the claim that creatine protects bone.
  • October 2026Longevity protocol by age: Reversed the claim that CoQ10 is strongly recommended with statins (a meta-analysis found no benefit) and removed recommendations for MTHFR testing and whole-body MRI screening.
  • October 2026Protocol for men with low testosterone: Removed claims that testosterone therapy improves cognition and that vitamin D raises testosterone; trials found neither.
  • October 2026Protocol for post-menopausal women: Corrected bone-loss figures and aligned hormone therapy guidance with the 2022 menopause society position statement.
  • October 2026Heart disease protocol: Corrected the blood pressure effect of magnesium (about 2 mmHg) and the evidence on colchicine.
  • October 2026Type 2 diabetes protocol: Corrected the effect of walking after meals and cardiovascular risk figures, and removed claims that several supplements lower blood sugar.
  • October 2026Chronic kidney disease protocol: Corrected kidney-disease risk figures and set protein targets to the KDIGO 2024 guideline.
  • October 2026Thyroid protocol: Removed unsupported "optimal" TSH and free T3 targets.
  • October 2026Fatty liver protocol: Corrected the cardiovascular risk figure and the claim that time-restricted eating helps independently of calories.
  • October 2026PCOS protocol: Corrected cardiovascular risk claims and the strength of the evidence for inositol.
  • October 2026Protocol after cancer: Corrected vitamin D claims: the trials did not show lower cancer recurrence.
  • October 2026Anxiety and depression protocol: Removed claims that some supplements work as well as SSRIs.
  • October 2026ADHD protocol: Removed advice to take stimulant medication with antacids, which can raise amphetamine levels.
  • October 2026Autoimmune disease protocol: Corrected the VITAL trial result and removed high-dose vitamin D advice.
  • October 2026Chronic pain and fibromyalgia protocol: Corrected claims about low-dose naltrexone, vitamin D and creatine for pain.
  • October 2026Supplement interactions: Corrected an overstated berberine and metformin risk and other interaction claims.
  • October 2026Fasting insulin and HOMA-IR: Removed "longevity-optimal" targets that no study supports.
  • October 2026Sauna and longevity: Corrected the mortality figures, the length of follow-up and a growth hormone claim to match the studies.
  • October 2026NAD+ and sirtuins: Corrected the description of the main NMN trial: it studied women with prediabetes, not older men.
  • October 2026Rapamycin and mTOR: Clarified that the 9% and 14% mouse results measured maximum lifespan, not median lifespan.
  • October 2026Is rapamycin safe?: Corrected statements that the PEARL trial's results were still pending.
  • October 2026Psychedelic medicine: Added the FDA's 2024 decision not to approve MDMA-assisted therapy and corrected trial details for MDMA and psilocybin.
  • October 2026Longevity genomics: Updated the genetic share of lifespan (well below 10% in the largest analysis) and cancer-gene risk figures.
  • October 2026Omega-3 fatty acids: Corrected a citation that credited a 2018 analysis with trials published later, and the typical US omega-3 level.
  • October 2026Protein and longevity: Corrected protein advice for adults over 65 to the expert recommendation of at least 1.0 to 1.2 g/kg a day. In October 2026 we also removed a stated protein target for longevity of 1.6 to 2.2 g/kg, corrected the age group in the cited mortality study (50 to 65) and reported its findings in both directions.
  • October 2026Zone 2 training: Removed unsupported minimum-dose claims and a claim that Zone 2 training outperformed metformin.
  • October 2026Testosterone and TRT: Corrected the age-related decline figures and TRAVERSE trial details, and removed dosing specifics the sources do not support.
  • October 2026Red light therapy: Corrected the list of uses endorsed by the 2025 dermatology consensus and removed an inaccurate NASA story.
  • October 2026Exosomes: Corrected the description of the FDA's 2019 safety notice.
  • October 2026FDA peptide reclassification: Corrected the status of Melanotan II, which left the FDA's restricted list in April 2026.
  • October 2026GLP-1 agonists: Restated a "proven" mortality claim as the actual trial results.
  • October 2026Longevity for women: Corrected hormone therapy and cardiovascular timing claims.
  • October 2026The longevity supplements guide: Corrected what the VITAL trial showed and removed an unsourced market figure.
  • October 2026Course: Optimize Your Bloodwork: Replaced "longevity-optimal" lab ranges with guideline categories, corrected an Lp(a) unit error and a vitamin D example that contradicted NIH guidance, and fixed a statistic that mixed up two studies.
  • October 2026Course: Longevity Fundamentals: Replaced invented "optimal" targets in the biomarker lesson with guideline categories.
  • October 2026Menopause biomarker tracking guide: Replaced invented "optimal" ranges with guideline and reference categories, and corrected testing advice that contradicted the Endocrine Society and US Preventive Services Task Force.
  • October 2026Folate vs folic acid: Rewritten. It told people with MTHFR variants to avoid folic acid, although its own cited trial found folic acid and methylfolate lower homocysteine equally. Added that folic acid is the form recommended for anyone who could become pregnant, and retitled the article to match.
  • October 2026Homocysteine: Rewritten. Corrected the VITACOG trial (it used folic acid, not methylfolate, and its 53% result was whole-brain shrinkage), replaced an overstated heart-risk figure with the meta-analysis result, added the trials in which B vitamins did not prevent heart attacks, and removed an invented "longevity target" table.
  • October 2026Longevity nutrients glossary: Corrected the folate entry, which advised methylfolate instead of folic acid and gave an invented homocysteine target.
  • October 2026Genetic risk factors guide: Removed advice to avoid folic acid and fortified foods for people with two copies of the MTHFR C677T variant; a randomized trial shows folic acid works for them.
  • October 2026Your 50s guide: Replaced "methylfolate, not folic acid" with trial evidence that both lower homocysteine.
  • October 2026Longevity Fundamentals course: Rewritten lesson by lesson with 30 sources. Removed claims that exercise cuts Alzheimer's risk by 45% and that sleep loss accelerates every hallmark of aging, an invented "80/20 of longevity" (also a quiz answer) and a quiz citing a study that does not exist; corrected the hallmarks of aging and the evidence grades.
  • October 2026Optimize Your Bloodwork course: Rewritten with 20 sources. Removed invented "optimal" targets for insulin, HOMA-IR, hsCRP, homocysteine, DHEA-S, ApoB and TSH, a vitamin D target that contradicted NIH guidance, prices and a false 12-hour fasting rule; fixed an Lp(a) unit error.
  • October 2026Exercise for Longevity course: Rewritten with 22 sources. Corrected a fitness study attributed to the wrong journal, removed unsourced figures (45% lower Alzheimer's risk, muscle loss per decade), the claim that protein must be eaten within two hours of training, and unsourced deload and decade-by-decade prescriptions.
  • October 2026Sleep Optimization course: Rewritten with 27 sources. Removed invented evidence grades for sleep supplements, an overstated immune figure, an unsourced bedroom temperature, device prices and the claim that melatonin suppresses natural production; added that CBT-I is the recommended first treatment for chronic insomnia.
  • October 2026Build Your Protocol course: Rewritten with 13 sources. Supplement grades now match the Supplement Evidence Database (the course had graded vitamin D and omega-3 "A"; the database grades them D and C); removed every price and an invented claim that lifestyle covers 80% of achievable benefit.
  • October 2026Wearables & Testing Decision Guide: Rebuilt on 11 published validation studies. Removed outdated device models and every price, unsourced claims such as "the gold standard for sleep tracking" and "a $40 band captures 80% of the value", and a price comparison of testing services; added what validation studies show for steps, heart rate, HRV, sleep, VO2 max and glucose.
  • October 2026Longevity nutrients glossary: Rewritten with 24 sources. Removed eight invented "optimal" targets (for example vitamin D at 40-60 ng/mL and selenium at 120-150 µg/L) and unsourced dosing advice; each nutrient now shows its US reference intake, who is at risk of low levels and what trials found, including that 200 µg of selenium a day was linked to more type 2 diabetes. Retitled; it no longer promises "optimal levels".
  • October 2026Homepage: Removed claims that every article is 2,000+ words and peer-reviewed (articles vary in length and are not peer-reviewed) and that the site tracks 63 biomarkers (the biomarker guide covers 42), plus an unsourced claim that what is optimal at 30 can be counterproductive at 60. The tools section claimed nineteen tools but showed fifteen, one of them the newsletter; it now lists nineteen.
  • October 2026Nutrition calculator: Protein rules, fiber and micronutrient targets now follow published sources: protein starts at 0.8 g/kg and rises to 1.2 g/kg over 65 or for fat loss and 1.6 g/kg with resistance training; micronutrient targets are US reference intakes instead of invented doses such as 2,000 to 5,000 IU of vitamin D; a fiber calculation bug was fixed; unsourced claims about an optimal eating window, a leucine threshold and post-workout timing were replaced. A methods section with 19 sources was added.
  • October 2026Personal dashboard: The dashboard was a non-working template: it showed placeholder text instead of a form and could not log, chart or summarize anything, and it promised "optimal ranges" and a longevity score that no validated method supports. It now logs lab panels in your browser, charts each biomarker over time and labels every value with the same cited guideline categories as the Lab Results Interpreter; the report card is now a plain summary with sources.
  • October 2026Longevity cost calculator: Supplement descriptions now match our evidence database (several had contradicted it), and doses above safe upper limits were corrected: vitamin D had been priced at 5,000 IU a day and magnesium at 400 mg. Removed the claim that methylfolate is critical with MTHFR variants, whole-body MRI presented as cancer screening, brand names, invented prices for budget alternatives, and example protocols attributed to named people. Prices are now editable and labelled as rough estimates.
  • October 2026Protocol cost comparison: Removed invented figures for the share of longevity benefit at each budget (70% to 97%) and the curve built on them, a comparison of protocols attributed to named people and a supplement company, and grades that contradicted our evidence database (vitamin D and omega-3 had been graded A). Every item now carries the kind of evidence behind it, with sources, and prices come from the same list as the cost calculator.
  • October 2026Protocol builder: The builder never worked for visitors: it called an AI service from the browser without credentials, so every request failed. When it did run (in testing), it asked the AI for "optimal" targets and doses without sources and labelled the result "medically referenced". It now builds your plan in your browser from fixed rules, each tied to a guideline or trial: habits, notes on conditions a clinician has flagged, the US screening schedule for your age and sex, and supplement grades from our database, with 25 references.
  • October 2026Protocol Showdown: Removed invented scores from 1 to 10 for every outcome, the totals built on them, and claims of 10 matchups and 60 or more studies (there were 5 matchups and no linked references). Each row now says which option human studies favor, if either, with the study behind it; verdicts were rewritten from 20 verified studies, and NMN versus NR now follows our supplement database.
  • October 2026Hallmarks of aging explorer: Aligned with the 2023 hallmarks review: disabled macroautophagy is now a primary hallmark (it had been filed with the antagonistic ones). Removed 66 unsourced evidence grades defined as strong human trials, a protocol coverage score built on unsupported mappings, and research biomarker lists including a branded test. Each hallmark now has a sourced definition and lists only interventions tested in people, with the study cited.
  • October 2026Heart rate variability article: Corrected a misreported meta-analysis (a 2013 study of first cardiovascular events had been described as a 2021 study of mortality), the heart's pacemaker rate and the history of HRV research; removed unsourced figures and brand names; added the original post-heart-attack studies and two biofeedback meta-analyses.
  • October 2026Neuroplasticity article: Adult hippocampal neurogenesis is now presented as the open dispute it is, with studies on both sides; corrected the taxi-driver finding (larger posterior, smaller anterior hippocampus) and the citation for adult neurogenesis; removed unsourced claims about BDNF, fasting and sleep.
  • October 2026VO2 max article: Corrected the Cleveland Clinic findings and the rate of VO2 max decline (the cited meta-analysis found it similar whatever the training status, not halved by exercise); replaced a reference table taken from a popular book; removed unsourced figures, superlatives and brand names; added the original exercise-capacity study and the US activity guidelines.
  • October 2026Chronic stress and cortisol article: Removed a false claim that a study of stressed mothers measured DunedinPACE (it measured telomeres, and DunedinPACE did not exist until 2022), an unsupported claim that cortisol directly causes abdominal fat gain, superlatives and brand names; brain and immune effects are now described as the cited studies report them, and two references were added.
  • October 2026Healthy aging at 70 and beyond: Corrected protein advice (1.6 to 2.0 g/kg had contradicted the expert recommendation our nutrition calculator uses: at least 1.0 to 1.2 g/kg, more if active or ill) and polypharmacy figures; removed unsourced falls and fracture statistics and superlatives; added studies on grip strength, polypharmacy, protein and falls prevention.
  • October 2026Zinc and immune aging: Replaced unsourced intake, dosing and food figures with NIH values (RDA 11 mg for men and 8 mg for women, upper limit 40 mg); removed an unsupported prevalence figure, an outdated oyster value and unsourced claims about the thymus and a European study; added the main trial in older adults, noting its dose exceeded the upper limit.
  • October 2026Centenarian biology: Corrected a claim that centenarians have lower IGF-1 (the cited study found receptor mutations with higher IGF-1) and an outdated rarity figure; removed unsourced metabolic, immune and psychological generalizations so every claim matches its reference.
  • October 2026Prolonged fasting and the fasting-mimicking diet: Removed promotion of a branded kit, an unsourced hour-by-hour autophagy timeline, a misattributed epigenetic-clock claim and unsourced dosing advice; trial results are now reported as published, with the 2024 biological-age analysis described accurately.
  • October 2026Caloric restriction and longevity: Corrected the CALERIE results (participants achieved about 12% restriction, and the trial slowed one aging measure but not others), added the primate study that found no survival benefit, removed animal lifespan figures and an IGF-1 claim the sources did not support, and replaced protein advice of 1.6 to 2.2 g/kg with the expert recommendation for older adults.
  • October 2026Longevity pharmacology review: Corrected the acarbose mouse result (22% longer median lifespan in males, not 17%), limited the SELECT result to semaglutide, sourced the empagliflozin figures to their trial, removed off-label rapamycin doses, unsourced mechanism claims and an internal cross-reference, and added five references.
  • October 2026Longevity practitioner comparison: Removed an unsourced fee claim about a named physician and company endorsements, disclosed that the rapamycin trial we cite was run by employees and shareholders of a company that prescribes rapamycin, and made the advice on off-label medicines neutral.
  • October 2026Metformin for longevity: Re-verified the article. It listed the same paper twice as references 3 and 4; the duplicate is replaced by a 2022 Danish study, including twins, which found higher mortality with metformin-treated diabetes than without diabetes, so the earlier finding that metformin users outlive people without diabetes is now presented with that counter-evidence. Replaced unsourced figures (10 to 30 percent B12 deficiency, 20 to 30 percent with stomach side effects) and a B12 supplement prescription with the Diabetes Prevention Program results, sourced the exercise concern to two trials, removed an unsourced claim about what physicians recommend, and corrected conflicting statements about the TAME trial's status.
  • October 2026Longevity for women: Rewrote the guide to match its sources and the corrected HRT evidence. Removed claims that hormone therapy started within 10 years of menopause "supports cardiovascular protection" and "potentially cognitive protection" (a cited randomized trial found estradiol neither helped nor harmed cognition), an unsourced "30-40 percent fracture risk reduction", and unsourced figures (a 5 to 7 year life-expectancy gap, now 4.9 years per CDC 2024 data; estradiol levels; 2 to 3 percent yearly bone loss; women as 80 percent of autoimmune cases; Hashimoto's 7 to 10 times more common). Replaced a routine biomarker list with the USPSTF osteoporosis screening recommendation and framed one cited paper's case for hormone therapy as an argument rather than a finding. Two references added.
  • October 2026Longevity for men: Rewrote the guide to match its sources and current screening recommendations. Removed advice that contradicted the US Preventive Services Task Force (monthly testicular self-examination, which the USPSTF recommends against; PSA velocity tracking from age 40 to 45, where the USPSTF advises an individual decision at 55 to 69 and against screening from 70) and routine coronary calcium and bone scans. Replaced unsourced figures (a 5 to 7 year life-expectancy gap, now 4.9 years per CDC 2024 data; 30 to 40 percent fewer appointments; 1 to 2 percent testosterone decline per year) and targets (ApoB below 70, fasting insulin below 7, testosterone below 300). A cited study of a population-wide decline in testosterone across birth cohorts had been used as evidence of age-related decline. Four references added.
  • October 2026Hormones and longevity: Rewrote the guide to match its sources. Removed unsourced figures (testosterone "1 to 2 percent per year" and "35 percent lower by 70", growth hormone "14 percent per decade", DHEA-S "80 to 90 percent", normal testosterone ranges and a hematocrit cut-off), the claim that TRAVERSE "definitively resolved" testosterone safety, statements contradicting the HRT evidence ("critical window now well-established", transdermal estradiol "avoids" clot risk), an IGF-1 claim attributed to centenarian studies, growth-hormone peptide promotion, untreated-TSH and DHEA dose advice. Added the Testosterone Trials, the 2022 Menopause Society statement, a growth hormone systematic review, an IGF-1 survival study and a thyroid meta-analysis.
  • October 2026HRT for women: Rewrote the article to match its sources and retitled it from "The Evidence-Based Case for Hormone Therapy" to "What the Evidence Shows". The timing benefit within 10 years of menopause was not statistically significant (heart disease hazard ratio 0.76); transdermal estrogen was not linked to clots in an observational study, rather than shown not to raise risk; breast cancer risk in the E3N cohort was not "driven entirely" by synthetic progestins (estrogen alone also raised it), and a 2019 meta-analysis found raised risk with every systemic type; US prescriptions fell 66% (Prempro) and 33% (Premarin), not "more than 50 percent". Removed a dose and brand recommendation and replaced an unsourced recommendation table with the 2022 Menopause Society position statement. Four references added.
  • October 2026Methylene blue: Corrected the history sentence to what its source says (Paul Ehrlich noted methylene blue's antimalarial action in the late 19th century, and it is still used for methemoglobinemia), aligned the serotonin-toxicity paragraph with its sources (severe toxicity at an intravenous dose of 1 mg/kg; all proposed uses reach levels that block MAO) and removed advice to use "established low doses", since no dose has been established for longevity use.
  • October 2026Berberine: Corrected the description of the most cited trial: it was a pilot study that randomized 36 adults with newly diagnosed diabetes to berberine or metformin and gave berberine to 48 more, not a trial of 116 patients, and the percentage reductions given did not appear in the paper. Removed dosing and titration advice, unsourced side-effect and cholesterol figures, speculation about gut bacteria and a claim that berberine may be preferable to metformin for active people; marked mechanism findings as laboratory results; sourced the drug-interaction warning to a human study.
  • October 2026Is rapamycin safe for healthy humans?: Corrected the opening, which still described rapamycin as the only drug to extend lifespan in every model organism tested: it extends lifespan in mice, and blocking its target extends lifespan in yeast, worms and flies. Removed an unsourced claim that thousands of people take it, re-sourced the side-effect list (the claim that mouth sores are the most reported side effect at longevity doses was not in the cited survey), and added two findings from the sources: transplant use also affects fertility, and the 2026 exercise trial recorded a higher total burden of adverse events with sirolimus.
  • October 2026Longevity protocol with fatty liver (NAFLD): Replaced the claim that a FIB-4 under 1.3 "effectively rules out" advanced fibrosis with the published figure: in the study that introduced the score, values below 1.45 ruled it out with a negative predictive value of 90% (reference added).
  • October 2026Kidney health and longevity: Updated the definition of eGFR: the current CKD-EPI equations (2021) use creatinine, cystatin C or both with age and sex, and no longer include race; the article had described race as part of the calculation.
  • October 2026Glossary: Corrected definitions to match their sources: IGF-1 (the cited study followed people in their nineties, and the survival benefit was in women) and melatonin (the trial measured sleep efficiency, which a 0.3 mg dose restored), and alpha-ketoglutarate (the cited mouse study reports levels that change with fasting, exercise and aging, and gives no basis for a claim about human studies); added technical definitions with sources to 17 molecular terms and 22 new molecular terms. Later the same day we corrected four more definitions to match their sources (mitophagy, brown fat, visceral fat and myokines) and added a cells and tissues section.
  • October 2026Biomarkers and testing hub: Removed an unsupported claim that a fasting glucose of 99 mg/dL already reflects insulin resistance, and an overclaim that the section covers every biomarker that matters; the introduction now rests on three cited studies.
  • October 2026Supplements hub: Removed an unsourced industry-size figure and a promise of optimal dosing; the introduction now rests on the VITAL trials and a creatine meta-analysis.
  • October 2026Exercise hub: Corrected a misread statistic: the fivefold mortality difference compares the least fit with the most fit, not the bottom quarter with above average. Removed an unsourced muscle and bone decline figure; claims now cite four studies.
  • October 2026Nutrition and fasting hub: Removed the false claim that calorie restriction extends lifespan in every model organism tested and an overclaim about the Mediterranean diet; the introduction now cites PREDIMED, CALERIE and a time-restricted eating trial.
  • October 2026Sleep hub: Removed an unsourced mortality figure for short sleep and an unsupported claim that sleep loss accelerates epigenetic aging; the introduction now cites three studies.
  • October 2026Brain and cognition hub: Replaced an overstated claim that cognitive decline is substantially modifiable, and a sleep and amyloid claim presented as settled, with two cited randomized trials.
  • October 2026Hormones and peptides hub: Removed the claim that thyroid hormones decline with age alongside testosterone, growth hormone and DHEA, and a promise of dosing protocols; the introduction now cites TRAVERSE, the 2022 menopause hormone therapy guidance and SELECT.
  • October 2026Alzheimer's prevention: Corrected the FINGER trial result (it was described as a 25% improvement in cognitive performance; the actual difference was 0.022 per year on a composite score) and the claim that follow-on trials were generally positive (MAPT and preDIVA found no clear benefit). Replaced Lancet Commission figures that were attributed to Alzheimer's disease and mixed two reports with a sourced estimate, and removed unsourced APOE risk figures, screening intervals and blood test targets. Added the ACHIEVE hearing trial and the SPRINT MIND blood pressure trial.
  • October 2026Cancer screening: Corrected the description of the 2018 PSA recommendation (it updated the 2012 guidance; it was not a downgrade), noted that NordICC's reduction in colorectal cancer deaths was not statistically significant, and corrected PATHFINDER (38% of positive results were cancer, not two-thirds). Removed unsourced survival figures, a price, risk-factor counts and a PSA-velocity protocol; added the USPSTF lung, colorectal and cervical recommendations and three trials.
  • October 2026Coronary artery calcium scoring: Corrected the MESA figures (the 7.7-fold risk applied to scores of 101 to 300; scores above 300 carried 9.7-fold risk), noted that a zero score is less reassuring for smokers and people with diabetes, and replaced an unsourced action table with the 2018 cholesterol guideline's calcium-score rules. Removed unsourced reclassification, progression, radiation and price figures, and replaced two sources that have no abstract to check against.
  • October 2026ApoB: Corrected how two studies were described: in statin-treated patients, non-HDL cholesterol predicted events better than ApoB, which performed like LDL cholesterol, and INTERHEART's abstract reports an odds ratio rather than a head-to-head win. Removed an unsourced longevity target table, a statin non-responder figure, guideline claims without sources, drug doses, prices and lab vendors; added a review sourcing the one-ApoB-per-particle principle.
  • October 2026Lp(a): Corrected the heritability figure to its source (the apo(a) gene explains 91% of the variation, not 80 to 90 percent) and removed the claim that Lp(a) promotes blood clotting, which the 2022 European consensus does not support. Softened 'definitively established' causality to the sources' wording, dated the drug-trial status, and removed unsourced risk multiples, a prevalence figure, a price and guideline-like treatment targets.
  • October 2026Advanced cardiovascular testing: Rewrote the article. Its citations did not support its claims (a CIMT claim cited a popular book, and a CT angiography claim cited a fitness study), and it overstated CIMT, which adds little to standard risk scores. It now cites a CIMT meta-analysis, the SCOT-HEART and FACTOR-64 trials and the 2018 cholesterol guideline, and explains that CT angiography's benefit was shown in people with chest pain, not in screening people without symptoms.
  • October 2026Kidney health (October 2026 review): Corrected the description of the DAPA-CKD trial (it enrolled people with or without type 2 diabetes, not mostly people without it) and replaced a dialysis-diet paper cited for general kidney claims with a large meta-analysis of eGFR, albuminuria and mortality. Removed unsourced prevalence and filtration figures, 'longevity-optimized' targets, a blood pressure target, protein numbers and mechanism claims.
  • October 2026Liver health (October 2026 review): Cited the ESSENCE semaglutide trial correctly (its results had been attributed to the earlier phase 2 trial, misdated and described as pending approval), reported the phase 2 trial's non-significant fibrosis result, removed an incorrect claim about how the liver takes up fructose, and limited the GGT findings to what the cited study shows. Removed unsourced figures, progression rates and 'optimal' enzyme thresholds.
  • October 2026Biomarker Reference (October 2026 review): Corrected the IGF-1 entry (the cited study followed 184 people in their 90s, not people aged 95 and older), removed an Lp(a) threshold we could not verify against its source, replaced two sources that have no abstract and a commercial health page, and added units to every reference range.
  • October 2026Vitamin D (October 2026 review): Corrected the VITAL trial's cancer death result (a 17% lower rate that was not statistically significant, not a significant 25% reduction) and removed a claim that a meta-analysis found lower all-cause mortality, which cited a trial overview instead. Replaced an unsourced 40 to 60 ng/mL target and 'supplement aggressively' dosing with the 2024 Endocrine Society guideline, and added VITAL's autoimmune and fracture results.
  • October 2026Creatine (October 2026 review): Corrected two misattributed figures (a 1.37 kg lean-mass result now cites the 2017 meta-analysis it came from, and a memory claim now cites the 2018 review of six trials rather than a contested 2023 analysis), replaced an unsourced mechanism with the researchers' own caveat, and removed unsourced publication counts, food-content figures and water-retention numbers. Safety statements now rest on the 2017 ISSN position stand and a kidney-function trial.
  • October 2026Magnesium (October 2026 review): Corrected a diabetes claim that cited a small trial instead of the meta-analysis it described (now cited, with its 8% to 13% figure), replaced an unsourced '45 to 68 percent' intake figure with 48% from national surveys, and described the sleep evidence accurately (one small trial and a 2021 review rating the evidence low quality). Removed unsourced claims about soil depletion, preferred tests and supplement forms, and replaced an encyclopedia chapter with the NIH fact sheet.
  • October 2026Melatonin (October 2026 review): Corrected a dose claim attributed to 'MIT researchers' that cited a winter-depression study (it now cites the 2001 trial in which 0.3 mg restored sleep efficiency), cited the 2005 meta-analysis that had been listed but never used (melatonin shortened time to fall asleep by about 4 minutes), and added a study showing supplement labels are often inaccurate. Removed unverifiable usage figures, an unsourced jet lag protocol and an unsourced age-decline figure, and framed antioxidant findings as laboratory results.
  • October 2026Iron status (October 2026 review): Corrected the hemochromatosis figures (iron-overload disease in 28.4% of men and 1.2% of women with two copies of the gene, not 40% and 10%), removed a misattributed 'iron reduction hypothesis' and an unsourced 'optimal' ferritin range, and replaced unsourced ferritin thresholds with the WHO guideline's. Added the randomized FeAST trial, in which lowering iron did not reduce deaths, and noted the limits of the blood-donor study.
  • October 2026CoQ10 (October 2026 review): Corrected the Q-SYMBIO heart failure trial results (major cardiovascular events 15% versus 26%, all-cause death 10% versus 18%; the article had quoted figures not in the trial report) and cited the trial, which had been listed but never linked. Replaced a claim that CoQ10 is 'generally recommended' for statin users with two meta-analyses that reached opposite conclusions, and removed unsupported claims that ubiquinol is superior and unsourced dosing advice.
  • October 2026Supplement brand testing guide (October 2026 review): Replaced an unsourced claim that 20 to 30% of supplements fail their labels with a published label-accuracy study, limited the descriptions of NSF and ConsumerLab certification to what their own pages state, explained what FDA manufacturing rules do and do not guarantee, and removed unsupported superlatives and an unverified certification description.
  • October 2026Telomeres (October 2026 review): Sourced the claim that most cancers reactivate telomerase to the 1994 study it comes from (90 of 101 tumour biopsies), removed heritability, assay-variability and shortening-rate figures that the cited sources do not contain, and replaced an unsourced evidence table with an accurate description of a small, unrandomized lifestyle study. Added a 2018 meta-analysis showing a modest link with mortality and a genetic study showing longer telomeres are linked to higher risk of several cancers.
  • October 2026Yamanaka factors and partial reprogramming (October 2026 review): Updated an outdated claim that no human trials were under way: Life Biosciences dosed the first participant in a phase 1 trial of the partial-reprogramming therapy ER-100 in June 2026. Replaced an unsourced claim of 15 to 30 percent lifespan extension with the actual 2016 result (in a premature-ageing mouse model), corrected an overstatement of the 2006 discovery, removed unsourced funding figures, and replaced a popular book with a peer-reviewed source.
  • October 2026Air quality (October 2026 review): Corrected the figures from the American Cancer Society cohort (each 10 µg/m³ of fine particles was linked to about 4% higher all-cause, 6% higher cardiopulmonary and 8% higher lung cancer mortality, not 12% and 14%) and removed a false claim that air pollution kills more people than tobacco. Updated the death toll to the current WHO fact sheet, removed unsourced indoor-air, filter and exercise figures, and added the Dublin coal-ban study and a randomized air-purifier trial.
  • October 2026Longevity supplements guide (October 2026 review): Corrected the VITAL omega-3 result (the 28% reduction was in heart attacks, a secondary outcome, not cancer deaths), replaced 'test, do not guess' vitamin D advice with the 2024 Endocrine Society guideline, and brought the creatine and magnesium sections in line with their corrected articles (magnesium moved down a tier). Updated spermidine (a 2022 trial found no memory benefit) and urolithin A (endurance improved but the main outcomes did not), and restated the antioxidant evidence with the meta-analysis figures.
  • October 2026Autophagy (October 2026 review): Described the first urolithin A human trial accurately (a safety trial that changed markers of mitochondrial health, not a phase 2 trial demonstrating mitophagy) and cited it, which the article had not done. Replaced an unsourced table rating fasting protocols as having strong human evidence with an honest account: autophagy-boosting extends lifespan in mice, but no human trial shows a fasting schedule or supplement slows ageing this way.
  • October 2026AMPK (October 2026 review): Removed a claim that AMPK activity declines with age in muscle, liver and brain, which its cited study does not report (the study found lower mitochondrial function and PGC-1α in older muscle, now described accurately). Removed an inflated biochemical figure, unsourced lists of AMPK-activating compounds and overstatements that every proven longevity habit works through AMPK.
  • October 2026Alcohol (October 2026 review): Stated the UK Biobank genetic study's findings precisely (higher blood pressure and coronary risk at all amounts, rising steeply at heavier intake) instead of generalizing to all such studies, removed sleep claims its source does not make, and replaced a misquoted conclusion with the 2016 Global Burden of Disease wording. Added a 2023 meta-analysis of 107 studies and the 2022 analysis showing that risk varies with age.
  • October 2026Blue Zones (October 2026 review): Corrected three figures: the cited legume meta-analysis found 10% lower cardiovascular and coronary risk (not 17% lower all-cause mortality), California Adventists lived 7.3 years (men) and 4.4 years (women) longer than other white Californians (not about 10 years longer than the state average), and the Framingham network study covered obesity only. Removed unsourced superlatives about individual regions, and noted that the age-records analysis is a preprint.
  • October 2026Bone density and longevity (October 2026 review): Removed uncited figures (hip-fracture death and dependence rates, an osteoporosis prevalence figure and menopause bone-loss rates), an uncited trial, and osteocalcin claims cited to a study that did not report them. Corrected the LIFTMOR results (they are bone density changes, not T-score improvements), stated hormone therapy's fracture benefit together with its risks from the Women's Health Initiative, and added the US screening recommendation, protein guidance and three osteoporosis drug trials.
  • October 2026Bone density optimization guide (October 2026 review): Removed a false claim that hormone therapy is the only treatment that both stops bone loss and builds bone, an uncited table of bone-loss rates, an incorrect one-year mortality figure (the cited meta-analysis reports relative risks), and uncited nutrient and exercise figures. Corrected the LIFTMOR protocol (twice weekly, supervised, above 85% of maximum) and a jumping study described as being in postmenopausal women (it was in older men). Medications now cite their trials.
  • October 2026Budget longevity protocol (October 2026 review): Removed testing advice that contradicted the Endocrine Society's guidance against routine vitamin D testing, corrected the description of the VITAL trial's participants, updated creatine's memory evidence to a 2023 meta-analysis, and replaced an unverifiable death count with the study's confidence intervals.
  • October 2026Cellular senescence (October 2026 review): Corrected two descriptions of dasatinib plus quercetin studies: both were small open-label pilots (9 and 14 people), not phase 2 or placebo-controlled trials, and grip strength was not reported. Removed unsourced lifestyle and tissue claims, and cited the senolytics review that had been listed but not used.
  • October 2026Circadian rhythm (October 2026 review): Removed uncited figures (70% of workers with social jet lag, 80% of genes rhythmic), health links attributed to a study that reported only higher BMI, an unnamed 2022 study (replaced by a published e-reader study), and overstated claims about light and meal timing. The meal-timing trial is now described as the five-week proof-of-concept study it was.
  • October 2026Continuous glucose monitoring for non-diabetics (October 2026 review): Replaced an unsourced table of 'optimal' glucose targets for longevity with published reference values from healthy people, and labelled them as reference values rather than targets. Removed an example meal not found in the cited study and a company wrongly listed as a CGM maker. Food order, walking after meals and sleep claims now cite trials, with the populations studied stated.
  • October 2026Depression and longevity (October 2026 review): Removed an unsupported claim that depression ages the body by 7 to 10 years and uncited mortality multipliers. Corrected the heart-disease meta-analysis (21 studies and a relative risk of about 1.8, not 22 studies and a doubling; its authors say depression is not yet established as an independent cause), the inflammation meta-analysis (24 studies, not hundreds), and the date of the exercise meta-analysis (2024), whose low confidence ratings are now stated.
  • October 2026Exercise and the brain (October 2026 review): Corrected sources cited for claims they did not make: a blood-flow study had been cited for exercise effects, the hippocampus trial for Parkinson's, stroke and depression claims, and a resistance-training trial for a finding from a different paper. Noted that new-neuron growth is shown in mice and debated in adult humans, removed uncited mechanism and dose claims, and added a meta-analysis, a resistance-training trial and a Parkinson's trial.
  • October 2026Grip strength (October 2026 review): Replaced an unsourced table of grip-strength reference values by age with published British normative data, and presented weak-grip cut-offs as the definitions they are rather than mortality thresholds. Noted that the PURE study found no link between grip strength and falls or fractures, which the article had listed, and removed an unsourced claim about how fast older adults improve. Added the UK Biobank study.
  • October 2026HIIT vs steady-state cardio (October 2026 review): Corrected a reversed finding: the cited mitochondrial study found the biggest changes after sprint intervals, not steady low-intensity training. Labelled a heart-failure trial and an elite-athlete trial for what they were, replaced an unsourced training table with the US activity guidelines, and added Generation 100, the five-year trial that compared interval and moderate training for mortality.
  • October 2026Inflammaging (October 2026 review): Corrected a CRP target given in the wrong units (mg/dL instead of mg/L) and removed unsourced blood targets. The article had called inflammation a proven driver of ageing; its own main source says the causal role is largely unknown. Labelled mouse and cell findings, sourced the fermented-food trial (without an unsupported figure) and added the CANTOS trial with its caveats.
  • October 2026Red light therapy (October 2026 review): Cited a randomized trial for the skin-rejuvenation claim, which had no source; aligned the practical advice with the trials (light before exercise; the skin trial's twice-weekly schedule instead of an unsourced dosing plan); described the NASA research accurately; and removed a recommendation of vitamin D and omega-3 supplements that contradicted our Supplement Evidence Database.
  • October 2026Longevity cooking (October 2026 review): Removed a temperature error for when grilling carcinogens form, an incorrect cancer classification, and unsourced figures for marinating, lycopene, rinsing beans, phytates and soaking. The marinade and carotenoid figures now come from the cited studies, including the finding that very long grilling undid part of a marinade's benefit.
  • October 2026Longevity protocol after cancer (October 2026 review): Stated the breast-cancer alcohol figure accurately (about 7% per 10 g of alcohol a day, not per drink), added the exercise trial's higher rate of muscle and joint problems, and corrected a sentence that listed tamoxifen among bone-thinning treatments.
  • October 2026Low testosterone protocol (October 2026 review): Matched the yearly testosterone decline to the cited study, replaced a claim that sleep, stress and nutrients all significantly change testosterone (the cited sleep analysis found short-term sleep restriction had no significant effect) with the clearest evidence, weight loss, and marked an unsourced stress mechanism as uncertain.
  • October 2026Post-menopausal protocol (October 2026 review): Replaced an unsourced list of estrogen's protective effects, an overstated description of hormone therapy as the most impactful intervention, and unsourced claims about visceral fat and annual insulin testing with more cautious wording. The trial and cohort figures were checked against their sources.
  • October 2026ADHD protocol (October 2026 review): Retitled a section that called exercise the best ADHD medication (the cited meta-analysis found a small effect on core symptoms), removed an unsourced claim that ADHD-related behaviours independently accelerate aging and an unsourced medication-timing rule, and corrected how caffeine works (it blocks adenosine).
  • October 2026Anxiety and depression protocol (October 2026 review): Added two caveats its sources state: the link between depression and heart disease has not been established as causal, and confidence in the exercise evidence was rated low or very low. The other figures were checked against their sources.
  • October 2026Autoimmune protocol (October 2026 review): Removed an invented mechanism, an unsourced claim that magnesium and zinc are commonly depleted, and an overconfident ban on immune-stimulating herbs (the evidence is thin). Exercise amounts now come from the US guidelines, and the article notes that the rheumatoid arthritis heart-risk estimates varied widely and that the vitamin D result in VITAL was borderline.
  • October 2026Chronic pain protocol (October 2026 review): Corrected a claim that the Cochrane overview found no evidence of harm from exercise: it found few adverse events, mostly temporary soreness, but only a quarter of studies reported them. Also softened an unsourced claim that pain accelerates biological ageing and an unsupported claim about pain education.
  • October 2026Fatty liver protocol (October 2026 review): Noted that the study that introduced the FIB-4 score was in people with HIV and hepatitis C, not fatty liver, and replaced an alarmist heading. The trial and meta-analysis figures were checked against their sources.
  • October 2026Your 20s guide (October 2026 review): The guide had no references; it now cites 13 studies and guidelines. Removed an unsourced Lp(a) target, a suggestion to test MTHFR genes, a claim that fish oil protects the heart (the VITAL trial found it did not), a claim that depression accelerates epigenetic ageing, advice to screen everyone for STIs every year (US guidance targets younger women and others at risk), and unsourced claims about sleep, cold showers and skin ageing. Corrected three evidence labels.
  • October 2026Your 30s guide (October 2026 review): The guide had no references; it now cites 16 studies and guidelines. Removed invented 'longevity targets' for Lp(a), ApoB, fasting insulin, HOMA-IR, TSH and the omega-3 index; corrected fitness figures (41% and 23%, not 50% and 30%), the cervical screening schedule (HPV co-testing starts at 30, not 21) and the label for 130-139/80-89 blood pressure (stage 1 hypertension, not 'high-normal'). Fish oil and time-restricted eating claims now match their trials, and six evidence labels were corrected.
  • October 2026Your 40s guide (October 2026 review): The guide had no references; it now cites 17. Calcium scoring and DEXA scans are no longer presented as routine for everyone at 40 (they now follow guideline use), and annual hormone panels for perimenopause were removed. Removed invented targets (HbA1c under 5.2%, fasting glucose under 90, a 90-second dead hang). Corrected the testosterone decline rate, a fitness figure, a claim that CoQ10 is essential with statins (trials found no benefit for muscle symptoms), a claim that vitamin K2 moves calcium out of arteries (trials are mixed), and the evidence for routine skin checks (the USPSTF calls it insufficient).
  • October 2026Your 50s guide (October 2026 review): Corrected two errors: CoQ10 does not relieve statin muscle symptoms in trials, and hormone therapy is recommended for hot flashes and bone protection, not for heart or brain protection (two trials found no effect on cognition). Epigenetic clocks, cognitive screening, CT angiography and full-body MRI are no longer presented as recommended screening, and annual DEXA scans for every post-menopausal woman were replaced with guideline screening. Removed invented numbers (vitamin D 40-60 ng/mL, 20% bone loss in 5-7 years, a 40 g protein window, a B12 threshold) and unsourced dense-breast figures. 20 references added.
  • October 2026Your 60s guide (October 2026 review): The guide had no references; it now cites 14. Annual cognitive screening and annual DEXA scans were replaced with US guideline advice, an 'essential' supplement stack (high-dose omega-3, vitamin K2, CoQ10 and others) was removed, and multivitamins are no longer described as insurance (the USPSTF finds the evidence insufficient). Corrected overstated figures for hip fracture deaths, daily steps (the benefit levels off around 6,000-8,000 a day for people 60 and over) and hearing loss and dementia (a large trial found hearing aids did not slow cognitive decline), and removed unsourced balance and function targets.
  • October 2026Your 70s guide (October 2026 review): The guide had no references; it now cites 17. The protein advice (1.8-2.2 g/kg a day, 40-50 g at four meals) was roughly double the expert recommendation and now matches it (at least 1.0-1.2 g/kg after 65, 1.2-1.5 with illness). Corrected the Fiatarone study details, falls and step-count figures, a claim that being overweight improves survival (mortality rose at a BMI below about 22) and screening ages (now matching USPSTF statements), and removed six-monthly cognitive testing, annual DEXA scans and unsourced supplement claims.
  • October 2026Women's longevity hub (October 2026 review): Guide descriptions were updated to match the corrected guides: removed a '20% bone loss in 5-7 years' figure, 'DEXA targets', osteocalcin and 'optimal' lab ranges, and softened claims about trial exclusion and supplement metabolism.
  • October 2026Perimenopause guide (October 2026 review): A 'landmark 2024 GrimAge study' was misdescribed; the cited study (2016) found that earlier menopause was associated with faster epigenetic ageing. Hormone therapy is described as the 2022 menopause guideline does (favorable for hot flashes and bone loss when started early), not as heart protection. Corrected bone-loss and soy figures, removed vitamin D 40-60 ng/mL targets, unsourced hormone thresholds, routine six-monthly hormone retests, a DEXA scan for every woman at 45-50 and a claim about cortisol and interval training, and aligned the supplement table with our database.
  • October 2026HRT Decision Framework (October 2026 review): The tool told women with a family history of breast cancer that short-term hormone therapy does not meaningfully raise breast cancer risk; a worldwide analysis found risk raised even in the first 1-4 years of use, and the result now says so. Removed claims that hormone therapy may protect the heart or brain (guidelines support it for symptoms and preventing bone loss; two trials found no effect on cognition) and that it is the only treatment that builds bone, and corrected the hot flash figure to the Cochrane review's 75%. Choosing heart, brain or longevity goals now shows a note explaining this. An evidence section with five references was added.
  • October 2026Metabolic flexibility (October 2026 review): The concept was credited to the wrong researchers (it was developed by Kelley and Mandarino), and a study of athletes on long-term low-carbohydrate diets was presented as evidence for Zone 2 training; it now says what that study found (2.3-fold higher peak fat burning with keto adaptation). Removed claims that Zone 2 is the best-proven intervention and that time-restricted eating improves metabolic flexibility, presented everyday hunger and energy dips as experiences rather than tests, and added a review's caution that much apparent inflexibility reflects reduced glucose uptake.
  • October 2026Mitochondria and aging (October 2026 review): Urolithin A was described as the most credible mitophagy supplement and recommended after 50; its main trial missed its primary endpoints and our database rates it as not supported, so the article now says so. Corrected a claim that Zone 2 is the gold standard (the study cited was of interval training), the description of a sitting study (2-minute walks every 20 minutes, not every hour), and the 2023 hallmarks framework's classification of mitochondrial dysfunction, and removed unsourced figures for NAD+ decline, urolithin A production and an 'optimal' weekly training dose.
  • October 2026mTOR (October 2026 review): Mouse lifespan figures for rapamycin now match the cited study (at the 90% mortality point, 14% longer in females and 9% in males, starting at 600 days); a '10 to 25 percent' figure was removed. The 'mTOR cycling' routine is now described as a hypothesis from mTOR biology rather than a tested pattern, and the discovery date was corrected.
  • October 2026Muscle protein synthesis (October 2026 review): Corrected the description of anabolic resistance (resting synthesis and breakdown do not change with healthy ageing; muscle responds less to meals and exercise) and replaced unsourced per-meal targets (40+ g, 3-4 g leucine) with study figures (about 0.4 g/kg per meal for older men). Removed a claim that protein above a per-meal ceiling is simply burned (a 2023 study found 100 g produced a larger, longer response than 25 g), and added sources for protein distribution and daily needs.
  • October 2026Oral health and longevity (October 2026 review): Gum disease was described as causally linked to heart disease, diabetes and Alzheimer's, with claimed support from Mendelian randomization studies; the evidence shows a consistent association, and trials have not shown that gum treatment prevents heart attacks or strokes. Removed an uncited cardiovascular mortality figure and an outdated drug-trial statement, re-tied two references to what they actually report (pneumonia risk and global prevalence), and added sources for US prevalence (42% of adults 30 and older), the effect of gum treatment on HbA1c (0.43 points) and powered toothbrushes.
  • October 2026Athletes guide (October 2026 review): The guide had no references; it now cites five. Removed invented targets (ferritin, thyroid and hormone ratios, deep sleep and REM minimums, a calorie window), routine echocardiograms before 35 and an unsourced 'sweet spot' for weekly training. Corrected a sleep statistic (the 1.7-fold injury figure came from adolescents sleeping under 8 hours), the atrial fibrillation figure (about 2.5 times the odds in a meta-analysis), the longevity figure (elite athletes' mortality was about a third lower), the protein range, and omega-3 and creatine claims that went beyond the evidence.
  • October 2026Desk workers guide (October 2026 review): The guide said prolonged sitting raises mortality even in people who exercise; a meta-analysis of 16 studies found that about 60 to 75 minutes a day of moderate activity seemed to eliminate that extra risk, and the guide and FAQ now say so. Fixed broken formatting that carried invented targets for fasting insulin, HOMA-IR and visceral fat, corrected the step-count plateau by age, aligned vitamin D, magnesium, creatine and omega-3 advice with the evidence, and removed unsourced figures and a recommendation for blue-light glasses.
  • October 2026Frequent travelers guide (October 2026 review): The guide had no references; it now cites three. Removed advice to screen frequent flyers for Factor V Leiden, a claim that window seats deliver tanning-bed UV (the melanoma data concern pilots and cabin crew), a vitamin C and zinc travel regimen (regular vitamin C shortened colds by about 8% in a Cochrane review; short courses are untested) and a magnesium dose above the upper limit. Corrected the compression-stocking figure (symptomless clots in 3 vs 47 travellers in a Cochrane review) and removed unsourced hydration, light-box, radiation and jet lag figures.
  • October 2026Genetic risk factors guide (October 2026 review): Testing advice now follows guidelines: targeted testing based on family history instead of a broad panel including MTHFR and Factor V Leiden, and no annual cognitive tests or amyloid scans for people without symptoms. Niacin was suggested for high Lp(a); in the HPS2-THRIVE trial it did not reduce major vascular events and increased serious side effects, so it is now listed as not recommended. Fixed broken formatting that hid invented targets, removed high-dose omega-3 and curcumin claims, and corrected FAQ answers that said lifestyle can cut genetic risk by 40-80% or bring APOE4 carriers close to normal risk (a large study found healthy habits lowered dementia risk in people at high genetic risk, without erasing it).
  • October 2026High-stress professionals guide (October 2026 review): The guide had no references; it now cites two meta-analyses (job strain was linked to about 23% higher coronary risk; 55+ hour weeks to 33% higher stroke and 13% higher coronary risk). Removed uncited claims that stress ages you 2-6 years and raises heart risk 40-60%, fixed broken formatting that hid invented targets, stopped recommending salivary cortisol testing, and aligned ashwagandha (early evidence), magnesium and omega-3 advice with our database.
  • October 2026Outdoor and manual workers guide (October 2026 review): The guide had no references; it now cites three. The physical activity paradox is now sourced (men with high occupational activity had 18% higher early mortality in a meta-analysis). Replaced advice that annual dermatologist exams are essential (the USPSTF finds the evidence insufficient; self-checks and prompt review of changing moles are advised), corrected the hearing loss and dementia claim, aligned vitamin D, omega-3 and magnesium advice with the evidence, and removed unsourced figures.
  • October 2026Longevity by decade hub (October 2026 review): Descriptions were updated to match the rebuilt decade guides, including replacing 'longevity-optimal targets' with guideline ranges and removing an unsourced claim about training intensity by age.
  • October 2026Parents of young children guide (October 2026 review): The guide had no references; it now cites two. Removed invented targets (TSH, free T3, ferritin, fasting insulin) and annual thyroid tests for three years, corrected the father depression figure (about 10% in a meta-analysis), replaced a '15 cigarettes' comparison with meta-analysis figures, aligned magnesium, vitamin D and omega-3 advice with the evidence, and matched FAQ answers to the studies (parents' life expectancy at 60 was 2 years longer for men and 1.5 for women; parents' sleep had not fully recovered up to 6 years after a first child).
  • October 2026Parkinson's disease prevention (October 2026 review): The idea that Parkinson's begins in the gut was stated as fact; it is now described as one hypothesis (the staging study cited places the first lesions in the vagus nerve nucleus and olfactory system). Corrected the coffee figure (protection peaked at about 3 cups a day, relative risk 0.72, not 5% per cup), described the REM sleep behavior disorder study accurately (21 of 26 older men over 16 years), added a meta-analysis for physical activity (about 21% lower risk), dropped ibuprofen as a protective factor, fixed a mechanism error about rotenone and PINK1, and removed prevalence figures that could not be verified.
  • October 2026Sirtuins (October 2026 review): Calorie restriction, exercise, fasting and NAD+ precursors were described as proven sirtuin activators in humans; the evidence for sirtuin activation comes mainly from animal studies, and the article now says so. Removed an unsourced yeast lifespan figure and an overstated description of SIRT3-deficient mice, and described the resveratrol correction precisely (the original activation depended on a fluorescent tag used in the test).
  • October 2026Sleep stages and longevity (October 2026 review): The article said new memories are moved into long-term storage during REM sleep; this is mainly linked to deep sleep, with REM linked to emotional and procedural memory, and the article now says so. A 60% figure for brain waste clearance was corrected (it described the space between brain cells in mice), and claims about growth hormone, alcohol, REM loss and beta-blockers were made accurate.
  • October 2026Brain longevity blueprint (October 2026 review): Brain waste clearance during sleep was described as the brain's primary defense against Alzheimer's, with a 60% figure that came from mice; both are now stated accurately, and a one-night sleep loss study is cited for what it found (more amyloid in the hippocampus and thalamus). Corrected the Alzheimer's timeline to the inherited-disease study it came from, described the FINGER trial's benefit as modest, removed APOE risk multipliers not found in the cited review, replaced a misdescribed exercise meta-analysis with its actual findings (39 trials in adults over 50; 45-60 minute sessions), removed advice to get cognitive testing in your 40s, and noted the Lancet Commission's 2024 update.
  • October 2026The longevity mindset (October 2026 review): This page was a generic template with filler text and unrelated references, and it attributed a purpose-and-mortality finding to the Framingham Heart Study that we could not verify. It has been rewritten on the Ohsaki ikigai cohort (43,391 Japanese adults) and a meta-analysis linking higher purpose to lower mortality and fewer cardiovascular events (relative risk 0.83 for each), with the proposed mechanisms described as unproven.
  • October 2026Future of longevity medicine (October 2026 review): Fixed a text error in which 'precision medicine' had been replaced with our site name, corrected a reference to 2027, and noted that drugs for MASH (resmetirom in 2024 and semaglutide in 2025) are already approved rather than a future development. Early senolytic results and long-term lifespan forecasts are now described with appropriate uncertainty.
  • October 2026Longevity exercise blueprint (October 2026 review): Corrected the Cleveland Clinic fitness study: it found low fitness carried about 5 times the mortality risk of elite fitness, comparable to or greater than smoking or diabetes, not a 50% drop between the two lowest groups or the most powerful predictor ever found. A '2016 NEJM study' of 4x4 intervals could not be found; the article now describes the Generation 100 trial (1,567 adults averaging 72), in which training including intervals did not reduce mortality compared with recommended activity. Removed an unsourced claim that most exercisers train in a 'wrong' middle zone, aligned activity targets with US guidelines, and toned down myokine claims.
  • October 2026Mediterranean diet for longevity (October 2026 review): The article said, in two places, that a 2023 randomized trial showed the MIND diet slows cognitive decline; the trial it cited found no significant difference from a control diet over three years. It also described the cited 2014 study as PREDIMED-Plus cardiac results; that study is a PREDIMED analysis showing the olive-oil Mediterranean diet reduced type 2 diabetes risk (hazard ratio 0.60), and PREDIMED-Plus cardiovascular results are still awaited. Removed red wine and resveratrol as 'active ingredients', a claim that PREDIMED was the largest diet trial ever, and a comparison of MIND with drug trials, and framed telomere, epigenetic and cancer findings as observational.
  • October 2026Top 10 exercise myths (October 2026 review): Corrected a claim that the extra calories burned at rest by added muscle exceed those of most cardio sessions (the resting effect is small), and replaced a claim that mortality benefit plateaus at 150-300 minutes and reverses at high volumes with the cited running study (runners had 30% lower all-cause mortality, and under 51 minutes a week was enough). The sitting-time myth now reflects a large analysis finding that 60-75 minutes of daily moderate activity appeared to offset the mortality risk of long sitting.
  • October 2026Time-restricted eating (October 2026 review): The article merged two different trials into one ('a 2022 NEJM trial by Lowe et al. in 139 adults'), and two citation numbers pointed to the wrong studies. It now describes each correctly: a 12-week trial of 116 adults (Lowe, 2020) in which 16:8 eating did not produce more weight loss than eating throughout the day, and a 12-month trial of 139 adults (Liu, 2022) in which adding an eating window to calorie restriction made no significant difference. The early time-restricted feeding study is described accurately (a 6-hour window compared with a 12-hour schedule, not a late window), a claim that benefits are independent of calorie intake was corrected, and protein advice now matches our protein guidance.
  • October 2026VO2 max testing (October 2026 review): Corrected the Cleveland Clinic fitness study: the least fit had about 5 times the mortality risk of the fittest, comparable to or greater than smoking or diabetes, rather than a 50% drop between the two lowest groups or the strongest predictor of all. A heart rate accuracy study had been cited for wearable VO2 max error; it is now cited for what it measured (heart rate was generally accurate; calorie estimates were not). The percentile table is labeled as approximate.
  • October 2026Longevity Score (October 2026 review): The scoring was rebuilt. The previous version awarded points for unproven practices (taking supplements, fish oil, a vitamin D level of 40-60 ng/mL, time-restricted eating, dedicated Zone 2 sessions and HRV tracking), used invented 'optimal' ranges for glucose, insulin and waist size and outdated blood pressure categories, and did not score smoking. The new version scores ten areas against published guidelines and large studies, including a new smoking and alcohol section, and explains its method and limits.
  • October 2026Clinical Trial Tracker (October 2026 rebuild): The tracker was rebuilt from the ClinicalTrials.gov registry. The previous version cited no sources and several of its trial IDs pointed to unrelated studies: the PEARL rapamycin trial was linked to a melanoma test study and described as recruiting 1,000 people (it is completed, with 129 enrolled), TRIIM-2 and retatrutide were linked to unrelated trials, and TAME was given the ID of a different metformin trial (TAME has no registry record). Featured trials now show status, phase, enrollment and sponsor taken directly from the registry, summaries state only what published results report, and all 292 harvested trials are listed with links.
  • October 2026Research Radar (October 2026 rebuild): After its earlier studies were removed because they could not be matched to published papers, the page still displayed an 'Issue 5, April 2025' header describing those studies, including a 'landmark taurine aging trial' and a TAME trial update. That header has been replaced by Issue 1 (October 2026): nine human studies published July to September 2026, each linked to its PubMed record and DOI and summarised only from what the abstract reports, including two null supplement trials.
  • October 2026BDNF (October 2026 correction): The article gave a specific exercise prescription for raising BDNF (60-75% of VO2 max for 20-40 minutes) that the cited meta-analysis does not contain, and described a sustained rise in resting BDNF with regular training. The meta-analysis of 29 studies found a moderate rise after a single session, a larger rise in people who train regularly, only a small rise in resting levels, and smaller effects in studies with more women; the text now says that.
  • October 2026Shift workers guide (October 2026 follow-up): A figure on night-shift work and mortality (about 11% higher with 6 or more years of rotating night shifts) was not tied to a reference; it now cites the Nurses' Health Study analysis it comes from (hazard ratio 1.11), and an unverified cohort size was removed.
  • October 2026Frequent travelers guide (October 2026 follow-up): An FAQ answer said low-dose aspirin does not significantly reduce deep vein thrombosis compared with simpler measures, a comparison the guide did not source. It now says aspirin raises bleeding risk and is not routinely recommended for travel, and cites the Cochrane review showing compression stockings reduce symptomless deep vein thrombosis on long flights.
  • October 2026Parents guide (October 2026 follow-up): The finding that parents had longer life expectancy at 60 (about 2 years for men and 1.5 years for women) now cites the Swedish study it comes from.
  • October 2026Outdoor and manual workers guide (October 2026 follow-up): Removed three unsourced specifics: a collagen and vitamin C dose for tendons (only small early studies exist), a 3,000-5,000 calorie figure for heavy labor, and advice to move to lighter work by a particular age.
  • October 2026Gut-brain axis (October 2026 follow-up): Our October 3 correction described the fermented-food trial as a 10-week trial; it was a 17-week randomized study of 36 healthy adults. The duration has been corrected here and in the glossary.
  • October 2026Creatine (October 2026 retitle): The title said most people are 'underdosing' creatine, a claim the article does not support. It is now titled 'Creatine: The Best-Supported Supplement for Muscle Strength', matching the evidence the article describes. The page address is unchanged.
  • October 2026Fatty liver protocol (October 2026 retitle): The title used the older term NAFLD. In 2023 a multisociety consensus chose metabolic dysfunction-associated steatotic liver disease (MASLD) to replace it, so the title now reads 'Longevity Protocol with Fatty Liver Disease (MASLD)'. The article already explained the rename; the page address is unchanged.
  • October 2026Supplement brand testing guide (October 2026 retitle): The title promised to show which longevity supplements pass third-party testing, but the page explains how to check testing rather than listing brand results. It is now titled 'How to Check Third-Party Testing Before You Buy'.
  • October 2026Inflammaging (October 2026 retitle): The title said chronic inflammation 'drives every age-related disease', while the article's own source says its causal role is largely unknown. It is now titled 'How Chronic Low-Grade Inflammation Is Linked to Age-Related Disease'.
  • October 2026Walking for longevity (October 2026 review): The step-count meta-analysis was attributed to the wrong journal with figures it does not contain; it is now described as published (15 cohorts, 47,471 adults; benefits leveled off at 6,000-8,000 steps for adults 60 and older and 8,000-10,000 for younger adults). A claim that faster walking adds benefit beyond total steps was corrected (in that analysis, time at 100+ steps per minute was not significant), a post-meal glucose figure was replaced with what the cited review found about walking breaks during sitting, and the cognition meta-analysis is described accurately (39 trials).
  • October 2026Thyroid function and longevity (October 2026 review): Removed an 'optimal' TSH range of 1.0-2.5 and a claim that centenarians have TSH in that range; the study of centenarians we now cite found exceptional longevity was linked to higher TSH. Advice to test reverse T3 and free T3 routinely was replaced with guideline-based testing, the treatment section now cites the TRUST trial (737 adults 65 and older, no apparent benefit from treating subclinical hypothyroidism), and selenium for Hashimoto's is described as lowering antibodies in small trials without proven effect on progression, with its diabetes risk at 200 mcg a day noted.
  • October 2026Uric acid (October 2026 review): The article said genetic (Mendelian randomization) studies show uric acid causes high blood pressure; the study we now cite found no evidence of a causal effect on blood pressure or heart disease. Advice that urate-lowering drugs may be appropriate for high uric acid without gout was replaced with the American College of Rheumatology position and the ALL-HEART trial, in which allopurinol made no difference to heart attacks, strokes or cardiovascular deaths. An invented 'optimal' level and an unsourced soft-drink figure were removed.
  • October 2026Visceral fat (October 2026 review): Removed a claim that the SELECT trial showed visceral fat loss drove semaglutide's cardiovascular benefit (the trial did not measure visceral fat), an unverified 45% reduction figure, and a claim that dieting without exercise preserves visceral fat. The exercise meta-analysis is now described as reported: aerobic exercise reduced visceral fat compared with no exercise, and its advantage over resistance training was not statistically significant.
  • October 2026Wearables guide (October 2026 review): Device accuracy figures now come from validation studies: in a test of seven wrist-worn devices, heart rate was generally accurate but no device estimated calories with less than 20% error, and sleep staging agrees with lab studies only about half the time for deep sleep. Removed claims that two weeks of a continuous glucose monitor gives more insight than years of bloodwork and that blood-oxygen readings screen for sleep apnea.
  • October 2026Longevity nutrition blueprint (October 2026 review): Added the 2023 randomized trial of the MIND diet, which found no significant cognitive benefit over a control diet, alongside the earlier observational finding. Corrected the ultra-processed food figure to the cited umbrella review (21% higher all-cause mortality, highly suggestive evidence), clarified that PREDIMED showed fewer cardiovascular events rather than longer life, removed an inaccurate PREDIMED-Plus claim, and replaced claims that time-restricted eating consistently helps without eating less with the trial evidence, including a 12-month trial in which it added nothing to calorie restriction.
  • October 2026Gut-brain axis (October 2026 review): The article said gut bacteria produce about 95% of the body's serotonin; it is made by cells in the gut lining, with bacteria helping regulate production, as the cited study shows. Animal findings on butyrate and the brain are now labeled, probiotic mood evidence is described as mixed, an unsourced nerve-fiber count was removed, and a trial is cited in which a fermented-food diet increased microbiome diversity and lowered inflammatory markers.
  • October 2026Hallmarks of aging (October 2026 review): Removed the claim that rapamycin, metformin and others are approved longevity interventions (no drug is), and corrected rapamycin's late-start effect in mice to the cited study's figures (about 14% in females and 9% in males, not 20-30%). Also corrected the description of epigenetic clocks, labeled reprogramming and autophagy findings as animal research, noted that GDF11 is controversial, and described senolytic trials and centenarian microbiome findings as mixed.
  • October 2026Ketogenic diet and longevity (October 2026 review): The article cited 'multiple randomized trials' of keto for type 2 diabetes; it now describes the randomized trial (84 adults; medications reduced or eliminated in 95% on keto) and the Virta Health study separately, noting the latter was not randomized and that LDL rose about 10%. Microbiome effects are described as varying between studies, and an invented insulin-resistance threshold and a thermogenesis claim were removed.
  • October 2026Top 10 anti-aging claims debunked (October 2026 review): The page promised ten claims but covered only two, alongside generic template text and unrelated references. It now covers ten claims, each with its own source: growth hormone, detox diets, antioxidant supplements, multivitamins, fish oil, high-dose vitamin D, ginkgo, brain-training games, alkaline diets and stem cell clinics. An uncited industry revenue figure was removed.
  • October 2026Complete sleep optimization guide (October 2026 review): This page was a generic template with filler text and three references unrelated to sleep. It has been rewritten on five sleep-specific sources: sleep duration and mortality, caffeine timing (400 mg even 6 hours before bed disturbed sleep), exercise and sleep quality, melatonin's modest effects, and the American College of Physicians recommendation of CBT-I as the first treatment for chronic insomnia.
  • October 2026The epigenetic diet (October 2026 review): This page was a generic template with filler text and unrelated references, and it presented laboratory effects of green tea, curcumin and butyrate as proven gene reprogramming. It has been rewritten on human evidence: smoking's lasting effects on DNA methylation, rapid methylation changes in muscle after exercise, and a Mediterranean diet pilot that showed only a trend toward lower epigenetic age.
  • October 2026Evidence-based longevity protocol (October 2026 review): The protocol's targets have been aligned with clinical guidelines and our other corrected guides. Exercise now follows the US Physical Activity Guidelines (150-300 minutes of moderate activity plus muscle-strengthening on 2 or more days), vitamin D follows the 2024 Endocrine Society guideline (no routine testing or high-dose supplements in healthy adults under 75), and omega-3 advice reflects the VITAL trial. Removed invented lab targets (ApoB below 70 for everyone, fasting insulin, omega-3 index, homocysteine), a unit error in the hsCRP target, yearly epigenetic and DEXA testing, a rapamycin dose and an endorsement of NMN.
  • October 2026Sleep tracking with wearables (October 2026 review): Accuracy figures now come from the cited validation studies: trackers detect sleep well but wake poorly, and in one Oura test the ring underestimated deep sleep by about 20 minutes, overestimated REM by about 17 and agreed with the lab on deep sleep about half the time. Removed an uncited market figure, an invented example and a claim that checking sleep data raises cortisol.
  • October 2026Social connection and longevity (October 2026 review): The 50% survival finding from 148 studies was attributed to the wrong meta-analysis; it comes from the 2010 study, now cited, while the 2015 study found 29%, 26% and 32% higher mortality for isolation, loneliness and living alone. Removed a '15 cigarettes' comparison not found in either study and claims that cause and effect are confirmed, and added caveats to the oxytocin mechanism and the social contagion findings.
  • October 2026Strength training for longevity (October 2026 review): Grip strength was said to predict cancer mortality better than blood pressure; the PURE study found it predicted all-cause and cardiovascular mortality more strongly, while its link with cancer varied. Corrected the muscle-loss description to match its source, described the dose-response for strength training accurately (largest benefit at about 30-60 minutes a week), narrowed a cancer survival claim to the breast cancer study cited, and toned down claims about irisin, BDNF and anti-tumor effects.
  • October 2026Skin aging and longevity (October 2026 review): A claim that sun exposure causes 80% of visible facial aging was attributed to a twin study that did not measure this; it has been removed. The sunscreen trial is now described as reported (in 903 adults under 55, daily SPF 15+ use led to no detectable skin aging over 4.5 years and 24% less aging than occasional use), a collagen trial that was listed but not cited is now described (69 women, improved elasticity), and claims about skin clocks, telomeres and omega-3 were toned down.
  • October 2026Sleep and longevity (October 2026 review): Brain waste clearance during sleep was presented as established in humans and sleep loss as one of the strongest Alzheimer's risk factors; the key study was in mice, and both points are now stated with that caveat. Replaced an unsourced optimal range (7.5-9 hours) with a meta-analysis linking both short and long sleep to higher mortality, added sources for the one-night amyloid scan study and a 14-day sleep restriction experiment, cited a sleep and immunity review that had been listed but not referenced, and removed an overstated growth hormone figure.
  • October 2026Sleep apnea and longevity (October 2026 review): The article said the consequences of sleep apnea are largely reversible with treatment; in the SAVE trial of 2,717 adults with moderate-to-severe apnea and existing cardiovascular disease, CPAP did not prevent cardiovascular events (average use was 3.3 hours a night). Added a source for the cardiovascular risk of untreated severe apnea (odds ratio 2.87 for fatal events), removed overstated claims about cognitive aging and brain imaging, and matched the prevalence figure to its source (936 million adults aged 30 to 69).
  • October 2026Longevity exercise blueprint (October 2026 review): A reference that was listed but not cited is now used: the muscle-loss figure was corrected to match it (3-8% per decade in inactive adults), along with its finding that 10 weeks of resistance training added about 1.4 kg of lean mass.
  • October 2026Thyroid function and longevity (October 2026 review): The AACE/ATA hypothyroidism guideline, listed but not cited, is now cited for the treatment recommendations it supports.
  • October 2026Peter Attia's Medicine 3.0 (October 2026 review): A duplicated reference was merged and each source is now tied to the claim it supports (the EPIC-Norfolk study found four healthy behaviours equivalent to being 14 years younger). Fasting insulin and HOMA-IR are no longer presented as standard tests, the TRAVERSE testosterone trial now includes its higher rates of atrial fibrillation, kidney injury and pulmonary embolism, and promotional language was toned down.
  • October 2026Polyphenols and longevity (October 2026 review): The article said green tea is linked to lower cancer mortality; the Japanese cohort cited found lower all-cause and cardiovascular mortality but not lower cancer mortality, and it now says so. Removed a claim that olive oil provides ibuprofen-like effects at dietary doses, an uncited blueberry trial and overstatements about the evidence, framed laboratory mechanisms as such, and removed a brand recommendation.
  • October 2026Animal and plant protein (October 2026 review): The opening claim that most adults need far more protein than the RDA was replaced with the sourced position used across the site. Added the main cohort finding (replacing processed red meat protein with plant protein was linked to 34% lower mortality), cited a review that had been listed but not referenced, and removed an unsourced 'grass-fed preferred' recommendation.
  • October 2026Retirees guide (October 2026 review): The guide had no references; it now cites nine. Cognitive screening and bone-density intervals now follow USPSTF guidance, the falls figure now matches a review of trials (23%), and the social isolation figures are now attributed to the right studies. Removed claims that resistance training is the only way to rebuild muscle, that a fit 75-year-old has the capacity of a sedentary 60-year-old, that hearing loss is the single largest dementia risk factor, and that creatine prevents dementia, and replaced a universal B12 dose with advice to test.
  • October 2026Shift workers guide (October 2026 review): The guide had no references; it now cites two meta-analyses (shift work was linked to about 9% higher odds of diabetes and 23% higher risk of heart attack). Removed invented targets hidden by broken formatting, six-monthly testing, salivary cortisol testing, advice to start cancer screening 5 years early and unsourced figures, and corrected FAQ answers (in a study of about 75,000 nurses, 6 or more years of rotating night shifts was linked to about 11% higher mortality).
  • October 2026Vegans and vegetarians guide (October 2026 review): The guide had no references; it now cites three. Added fracture risk from the EPIC-Oxford study (vegans had about 43% higher total and more than double the hip fracture risk of meat eaters), replaced a DEXA scan for everyone by 40 with guideline screening, fixed broken formatting that hid invented targets, corrected protein advice that contradicted itself, lowered a Brazil nut suggestion that could exceed the selenium upper limit, and removed unsupported claims about creatine and epigenetic ageing.
  • October 2026Female-specific exercise protocol (October 2026 review): Removed a phase-by-phase menstrual cycle training table: the meta-analysis it cited found performance changes across the cycle were trivial and that general guidelines cannot be formed. Removed a claim that interval training causes harmful cortisol responses in menopause, claims not supported by the references cited for them (recovery and fat use in women, Zone 2), and invented tracking targets. Corrected a fitness figure (five-fold mortality difference compares the least fit with the fittest 2.3%) and a testosterone comparison.
  • October 2026Menopause biomarker tracking guide (October 2026 review): The guide's text now matches its tables and cites its five references. Removed a DEXA scan for every woman at 45-50, six-monthly hormone and metabolic retests, hormone-level checks on HRT (treatment is judged on symptoms), and invented action thresholds (fasting insulin, ApoB above 90, a T-score of -2.0, vitamin D 40-60 ng/mL). The cholesterol change now cites SWAN data.
  • October 3, 2026Your 70s guide: The guide said the benefits of statins may plateau in very old age, without a source. It now reports the 2026 STAREE trial in adults 70 and older without heart disease: atorvastatin lowered major cardiovascular events by 30% but did not extend survival free of dementia or disability.
  • October 3, 2026Hormone therapy for women: Added the FDA's 2025-26 labeling change: heart disease, breast cancer and probable dementia removed from the boxed warning (information kept elsewhere in the label; the endometrial cancer boxed warning kept for estrogen-alone products), with links to the FDA notices.
  • October 3, 2026HRT decision framework: Noted the FDA's 2025-26 hormone therapy labeling change, with links to the FDA notices; the trial evidence the tool uses is unchanged.
  • October 3, 2026Blue Zones: The caveats section cited only a critic's preprint on age records; it now also reports the 2025 peer-reviewed response describing how centenarians' ages are validated, and notes that four zones are demographically validated while Loma Linda's evidence comes from the Adventist cohort.
  • October 3, 2026BDNF: Added a sourced section on what blood BDNF levels mean and why a single test result is hard to interpret. Removed unsupported claims that raising BDNF is among the most actionable brain strategies, that its link to Alzheimer's protection is causal, that several foods robustly raise it, and that curcumin raises it in human trials; diet evidence is now labelled as mainly animal research.
  • October 3, 2026Coronary artery calcium scoring: The article described the 2018 US cholesterol guideline as current. It now follows the 2026 ACC/AHA dyslipidemia guideline that replaced it: risk from the PREVENT-ASCVD equations (low under 3%, borderline 3-5%, intermediate 5-10%, high 10% or more), calcium scoring used selectively when a decision is uncertain, a zero score that may support deferring treatment in selected people, and restored LDL goals. The interpretation table was updated to match.
  • October 3, 2026Advanced cardiovascular testing: Replaced references to the 2018 US cholesterol guideline as current with the 2026 ACC/AHA dyslipidemia guideline, which uses calcium scoring selectively when a treatment decision is uncertain.
  • October 3, 2026ApoB: The 2018 cholesterol guideline was presented as current; the article now describes the 2026 dyslipidemia guideline's selective ApoB testing, its LDL reduction targets (30-49% at borderline or intermediate risk, at least 50% at high risk) and LDL goals, and notes the 2018 ApoB risk-enhancer threshold as the earlier rule.
  • October 3, 2026Lp(a): Updated from the 2018 cholesterol guideline to the 2026 dyslipidemia guideline, which recommends measuring Lp(a) at least once in adulthood and counts 125 nmol/L (50 mg/dL) or more as a risk-enhancing factor.
  • October 3, 2026Bone density: Added a missing safety point: stopping denosumab abruptly led vertebral fractures to rebound to untreated levels in its main trial, so people stopping it should switch promptly to another bone medication.
  • October 3, 2026GLP-1 agonists: Added the oral GLP-1 drugs approved since the article was written: the semaglutide tablet for weight management (December 2025) and orforglipron (April 2026), with their trial results and an indirect comparison.
  • October 3, 2026Mitochondria and aging: An undated claim that NAD+ precursor trials were 'ongoing', cited to a 2018 review, was replaced with what that review concluded (animal results still had to be tested in people), with a link to the article on what human trials have since found.
  • October 3, 2026Lp(a): The article presented Lp(a)-lowering drugs as awaiting outcome trials. It now reports that the first such trial, Lp(a)HORIZON of pelacarsen in 8,323 people with cardiovascular disease, was announced on September 4, 2026 to have missed its primary goal of reducing cardiovascular events despite lowering Lp(a), with a link to the company filing. The glossary entries for pelacarsen and olpasiran were updated to match.
  • October 3, 2026Metformin for longevity: Added two 2026 studies the article lacked: in the Diabetes Prevention Program follow-up, lifestyle change but not metformin lowered the risk of multimorbidity, and in the DEMFOS trial, adding metformin to an intensive lifestyle program did not improve physical function in older adults with obesity.
  • October 3, 2026Alzheimer's prevention: Added the US POINTER (2025) and LatAm-FINGERS (2026) multidomain lifestyle trials alongside FINGER, with their modest cognitive benefits and the caveat that effects on dementia itself are not yet known.
  • October 3, 2026Sleep optimization guide: Added a 2026 randomized-trial analysis in which cognitive behavioral therapy for insomnia slowed one epigenetic measure of aging in older adults, described as an early biomarker finding.
  • October 3, 2026Psychedelic medicine: Added a 2026 placebo-controlled feasibility trial of psilocybin for treatment-resistant depression in England's National Health Service, noting its small size and the need for a confirmatory trial.
  • October 3, 2026Bone density: Added a 2026 network meta-analysis of 124 exercise trials: brisk walking or jogging and combined aerobic-resistance exercise probably help preserve bone density, with low-certainty evidence that some exercise types reduce fractures.
  • October 3, 2026GLP-1 agonists: Added a 2026 comparison of 19 weight-loss drugs across 262 trials, including one-year weight loss for each and the finding that only injectable semaglutide was linked to lower all-cause mortality.
  • October 3, 2026Glossary: alpha-ketoglutarate: The entry said a calcium salt of alpha-ketoglutarate extended healthy life in mice; it now adds that the NIA's multi-site Interventions Testing Program found no lifespan extension in either sex (2026).
  • October 3, 2026Testosterone and TRT: The monitoring paragraph did not match the American Urological Association guideline it cited. It now gives the guideline's target of about 450 to 600 ng/dL (not 400 to 700), testosterone checks every 6 to 12 months on therapy (not every 3 to 6), estradiol testing only for men with breast symptoms, hematocrit and PSA testing before treatment, and the guideline's statement that there is no evidence linking testosterone therapy to developing prostate cancer. It also notes that AUA confirmed the guideline remains valid in 2024.
  • October 3, 2026Cancer screening: Added a dated note that a December 2024 USPSTF draft would make HPV testing the preferred cervical screening option from 30 to 65 and allow self-collected samples, and that it had not been finalized as of October 2026.
  • October 4, 2026GLP-1 drugs: Retatrutide's phase 3 results were described as company-reported only; the article now reports the peer-reviewed TRIUMPH-2 trial (The Lancet, 2026). Added the ACHIEVE-4 trial, which found orforglipron non-inferior to insulin for major cardiovascular events.
  • October 4, 2026HRT decision guide: Added a 2026 meta-analysis linking menopause caused by surgery or other treatment before age 45 with higher cardiovascular and all-cause mortality, described as an association.
  • October 4, 2026Your 50s, 60s and 70s guides: The age guides gave no vaccine guidance. Each now has a dated vaccine item that follows the CDC adult immunization schedule as amended April 27, 2026.
  • October 4, 2026Bryan Johnson's Blueprint: Attributed the $2 million a year figure to the 2023 Bloomberg profile, replaced a summary table that gave unsourced evidence labels and undated prices, and corrected the statement that rapamycin has no human trial (the PEARL trial tested it in healthy adults).
  • October 4, 2026Hallmarks of aging explorer: The hallmark descriptions and human-study findings appeared only after a click and were missing from the page's HTML; they are now on the page in an 'all 12 hallmarks at a glance' section.